Spots Global Cancer Trial Database for A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Official Title: A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Study ID: NCT06319820
Conditions
Study Description
Brief Summary: The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arkansas Urology, Little Rock, Arkansas, United States
Genesis Research LLC, Los Alamitos, California, United States
Genesis Research LLC, Sherman Oaks, California, United States
First Urology, Jeffersonville, Indiana, United States
Associated Medical Professionals of Ny, Syracuse, New York, United States
MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
Keystone Urology Specialists, Lancaster, Pennsylvania, United States
Urology Associates, Nashville, Tennessee, United States
Urology Austin, Austin, Texas, United States
Hadassah University Hospita - Ein Kerem, Jerusalem, , Israel
Contact Details
Name: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial
Affiliation: Johnson & Johnson Enterprise Innovation Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
